title: POINT/COUNTERPOINT: Systemic α-particles are likely to yield more important advances in radiotherapy than are protons.
authors.affiliation: Faculty of Medicine, University of Western Sydney, Liverpool, NSW 2150, Australia (Tel: 61 (0)2 9524 2502; E-mail: bja1940@optusnet.com.au).
authors.forename: Barry J
authors.initials: BJ
authors.lastname: Allen
authors.affiliation: Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington 98195 (Tel: 206-598-5971; E-mail: chvetsov@uw.edu).
authors.forename: Alexei V
authors.initials: AV
authors.lastname: Chvetsov
authors.forename: Colin G
authors.initials: CG
authors.lastname: Orton
mesh_terms: D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy; D009502:Neutrons / Q000627:therapeutic use; D061766:Proton Therapy / Q000379:methods*; D016499:Radioimmunotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D011522:Protons
chemical_list: D011522:Protons